FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3019707411> ?p ?o ?g. }

• W3019707411 endingPage "401" @default.
• W3019707411 startingPage "391" @default.
• W3019707411 abstract "Abstract Purpose AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in a large randomized trial to assess their ability to prevent recurrence in HER2 expressing breast cancer patients. The primary analyses found no difference in 5-year overall disease-free survival (DFS) but possible benefit in subgroups. Here, we present the final landmark analysis. Methods In this 4-arm, prospective, randomized, single-blinded, multi-center phase II trial, disease-free node positive and high-risk node negative breast cancer patients enrolled after standard of care therapy. Six monthly inoculations of vaccine (VG) vs. control (CG) were given as the primary vaccine series with 4 boosters at 6-month intervals. Demographic, safety, immunologic, and DFS data were evaluated. Results 456 patients were enrolled; 154 patients in the VG and 147 in CG for AE37, 89 patients in the VG and 91 in CG for GP2. The AE37 arm had no difference in DFS as compared to CG, but pre-specified exploratory subgroup analyses showed a trend towards benefit in advanced stage ( p = 0.132, HR 0.573 CI 0.275–1.193), HER2 under-expression ( p = 0.181, HR 0.756 CI 0.499–1.145), and triple-negative breast cancer ( p = 0.266, HR 0.443 CI 0.114–1.717). In patients with both HER2 under-expression and advanced stage, there was significant benefit in the VG ( p = 0.039, HR 0.375 CI 0.142–0.988) as compared to CG. The GP2 arm had no significant difference in DFS as compared to CG, but on subgroup analysis, HER2 positive patients had no recurrences with a trend toward improved DFS ( p = 0.052) in VG as compared to CG. Conclusions This phase II trial reveals that AE37 and GP2 are safe and possibly associated with improved clinical outcomes of DFS in certain subgroups of breast cancer patients. With these findings, further evaluations are warranted of AE37 and GP2 vaccines given in combination and/or separately for specific subsets of breast cancer patients based on their disease biology." @default.
• W3019707411 created "2020-05-01" @default.
• W3019707411 creator A5000796708 @default.
• W3019707411 creator A5010280271 @default.
• W3019707411 creator A5014713051 @default.
• W3019707411 creator A5017611009 @default.
• W3019707411 creator A5017750493 @default.
• W3019707411 creator A5018154779 @default.
• W3019707411 creator A5021492589 @default.
• W3019707411 creator A5021690080 @default.
• W3019707411 creator A5024425311 @default.
• W3019707411 creator A5024613613 @default.
• W3019707411 creator A5029062544 @default.
• W3019707411 creator A5033176108 @default.
• W3019707411 creator A5034838741 @default.
• W3019707411 creator A5035547335 @default.
• W3019707411 creator A5044161354 @default.
• W3019707411 creator A5050537038 @default.
• W3019707411 creator A5059850025 @default.
• W3019707411 creator A5065391640 @default.
• W3019707411 creator A5066061720 @default.
• W3019707411 creator A5066190550 @default.
• W3019707411 creator A5075148164 @default.
• W3019707411 date "2020-04-22" @default.
• W3019707411 modified "2023-10-01" @default.
• W3019707411 title "Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence" @default.
• W3019707411 cites W1913340502 @default.
• W3019707411 cites W1973855239 @default.
• W3019707411 cites W1992029528 @default.
• W3019707411 cites W2006629572 @default.
• W3019707411 cites W2015886648 @default.
• W3019707411 cites W2025490634 @default.
• W3019707411 cites W2035144728 @default.
• W3019707411 cites W2080595933 @default.
• W3019707411 cites W2094060692 @default.
• W3019707411 cites W2095156669 @default.
• W3019707411 cites W2101030466 @default.
• W3019707411 cites W2104599421 @default.
• W3019707411 cites W2112506009 @default.
• W3019707411 cites W2122971334 @default.
• W3019707411 cites W2128402413 @default.
• W3019707411 cites W2145231311 @default.
• W3019707411 cites W2149647856 @default.
• W3019707411 cites W2154203858 @default.
• W3019707411 cites W2155240407 @default.
• W3019707411 cites W2260659963 @default.
• W3019707411 cites W2328399718 @default.
• W3019707411 cites W2507448865 @default.
• W3019707411 cites W2605865590 @default.
• W3019707411 cites W2779426212 @default.
• W3019707411 cites W2883734274 @default.
• W3019707411 cites W2942554478 @default.
• W3019707411 cites W2965352578 @default.
• W3019707411 doi "https://doi.org/10.1007/s10549-020-05638-x" @default.
• W3019707411 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7188712" @default.
• W3019707411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32323103" @default.
• W3019707411 hasPublicationYear "2020" @default.
• W3019707411 type Work @default.
• W3019707411 sameAs 3019707411 @default.
• W3019707411 citedByCount "38" @default.
• W3019707411 countsByYear W30197074112020 @default.
• W3019707411 countsByYear W30197074112021 @default.
• W3019707411 countsByYear W30197074112022 @default.
• W3019707411 countsByYear W30197074112023 @default.
• W3019707411 crossrefType "journal-article" @default.
• W3019707411 hasAuthorship W3019707411A5000796708 @default.
• W3019707411 hasAuthorship W3019707411A5010280271 @default.
• W3019707411 hasAuthorship W3019707411A5014713051 @default.
• W3019707411 hasAuthorship W3019707411A5017611009 @default.
• W3019707411 hasAuthorship W3019707411A5017750493 @default.
• W3019707411 hasAuthorship W3019707411A5018154779 @default.
• W3019707411 hasAuthorship W3019707411A5021492589 @default.
• W3019707411 hasAuthorship W3019707411A5021690080 @default.
• W3019707411 hasAuthorship W3019707411A5024425311 @default.
• W3019707411 hasAuthorship W3019707411A5024613613 @default.
• W3019707411 hasAuthorship W3019707411A5029062544 @default.
• W3019707411 hasAuthorship W3019707411A5033176108 @default.
• W3019707411 hasAuthorship W3019707411A5034838741 @default.
• W3019707411 hasAuthorship W3019707411A5035547335 @default.
• W3019707411 hasAuthorship W3019707411A5044161354 @default.
• W3019707411 hasAuthorship W3019707411A5050537038 @default.
• W3019707411 hasAuthorship W3019707411A5059850025 @default.
• W3019707411 hasAuthorship W3019707411A5065391640 @default.
• W3019707411 hasAuthorship W3019707411A5066061720 @default.
• W3019707411 hasAuthorship W3019707411A5066190550 @default.
• W3019707411 hasAuthorship W3019707411A5075148164 @default.
• W3019707411 hasBestOaLocation W30197074111 @default.
• W3019707411 hasConcept C121608353 @default.
• W3019707411 hasConcept C126322002 @default.
• W3019707411 hasConcept C141071460 @default.
• W3019707411 hasConcept C143998085 @default.
• W3019707411 hasConcept C146357865 @default.
• W3019707411 hasConcept C151730666 @default.
• W3019707411 hasConcept C168563851 @default.
• W3019707411 hasConcept C188816634 @default.
• W3019707411 hasConcept C530470458 @default.
• W3019707411 hasConcept C71924100 @default.
• W3019707411 hasConcept C86803240 @default.

• next